Building a Ketamine Treatment Record: What to Track Beyond a Mood Score

A treatment record should answer more than whether a ketamine session felt different. Its purpose is to show whether depression, daily functioning, and safety are changing over time. A brief, consistent record can support a better conversation with the treating clinician without turning every hour into a test of whether treatment is working. It is especially useful when early improvement is uneven or when the treatment schedule changes.

Start before the first session

Write down the problems that led you to seek treatment: difficulty getting out of bed, inability to concentrate, loss of interest, or missed responsibilities. Then choose two or three concrete examples that matter personally. Being able to prepare lunch or return a friend's call may be more informative than the vague goal of feeling normal. Record these before treatment so that later expectations do not quietly replace the original baseline.

Ask which standardized depression measure the clinic uses and how often it will be repeated. A rating scale makes observations more consistent, but the number is not the diagnosis. Different scales use different ranges, so scores from unrelated questionnaires should not be placed on one graph as though they were interchangeable. If questionnaires are hard to complete, discuss a workable method rather than abandoning measurement altogether.

Keep the measurement window visible

The timing of an assessment changes what it means. In the Murrough et al., single-infusion ketamine randomized trial, 2013, the primary outcome was measured 24 hours after a single infusion. That is evidence about a rapid antidepressant effect, not proof of lasting recovery after one treatment. A score obtained during a session, the next morning, and several weeks later addresses three different questions. Label entries with the date and their relationship to treatment.

Try to complete routine questionnaires under reasonably similar conditions. Record major disruptions such as an illness, a night without sleep, or a medication change. This does not mean those measurements should be deleted; the context may be clinically important. It simply makes an apparent change easier to interpret. Ask the team whether they want daily observations or less frequent summaries, since excessive tracking can become burdensome.

Track functioning separately

Symptoms and functioning may move at different speeds. Someone may feel less despair before returning to work, while another person may resume chores despite persistent low mood. Separate entries prevent these patterns from being flattened into a single verdict. A useful record includes one emotional observation, one functional observation, and one safety concern, if present. Short, factual descriptions are usually easier to review than a long narrative written after every session.

Avoid treating productivity as the only meaningful outcome. Restoring appetite, tolerating a family conversation, or needing less prompting for basic self-care can matter. Conversely, a sudden burst of activity accompanied by very little sleep, unusually elevated mood, or impulsive spending deserves prompt clinical attention rather than automatic celebration. The treatment team should interpret such changes in the context of the person's diagnosis and history.

Make adverse effects part of the same record

Include nausea, dizziness, distressing changes in perception, urinary symptoms, and other new problems. Record when they started, how long they lasted, and whether they affected eating, walking, sleep, or responsibilities. Do not wait for a scheduled questionnaire to report severe or concerning symptoms. The Spravato prescribing information, FDA, 2025 describes monitoring requirements and important risks for esketamine; the record supplements that monitoring and cannot substitute for it.

Document instructions received from the clinic, including whom to contact between sessions. If another clinician changes a medicine, tell the treatment team rather than trying to determine causation yourself. Changes in several treatments at once make attribution harder, but coordinated care remains more important than producing a perfectly controlled personal experiment. Never stop prescribed medicines merely to make a tracking chart easier to interpret.

Use the record to make decisions

Before treatment, ask when the first formal review will occur and what would count as meaningful benefit, insufficient improvement, or unacceptable burden. Those categories should include travel, cost, recovery time, and adverse effects as well as symptom scores. A clinic should be able to explain how the record informs continuation or a change in approach. Read our consultation decision guide for a broader framework.

Maintenance introduces another question: whether improvement persists between treatments. The Daly et al., esketamine relapse-prevention randomized trial, 2019 examined relapse prevention among selected people who had already benefited from esketamine with an oral antidepressant. It does not provide a universal schedule for everyone starting ketamine. Our maintenance planning guide explains that distinction. Bring a concise summary to reviews and ask the clinician to explain the trend, not merely congratulate or dismiss one favorable or unfavorable day.

Medical disclaimer: This article provides general education, not diagnosis, individualized treatment advice, or emergency care. Evidence and regulatory statements refer to the dated sources cited, not an exhaustive verification of all changes through October 30, 2026.

Sources

1. Murrough et al., single-infusion ketamine randomized trial, 2013
2. Daly et al., esketamine relapse-prevention randomized trial, 2019
3. Spravato prescribing information, FDA, 2025